Loss of ADAR1 in tumours overcomes resistance to immune checkpoint blockade.

doi:10.1038/s41586-018-0768-9

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Loss of ADAR1 in tumours overcomes resistance to immune checkpoint blockade.

Nature - 1 Jan 2019

Ishizuka Jeffrey J, Manguso Robert T, Cheruiyot Collins K, Bi Kevin, Panda Arpit, Iracheta-Vellve Arvin, Miller Brian C, Du Peter P, Yates Kathleen B, Dubrot Juan, Buchumenski Ilana, Comstock Dawn E, Brown Flavian D, Ayer Austin, Kohnle Ian C, Pope Hans W, Zimmer Margaret D, Sen Debattama R, Lane-Reticker Sarah K, Robitschek Emily J, Griffin Gabriel K, Collins Natalie B, Long Adrienne H, Doench John G, Kozono David, Levanon Erez Y, Haining W Nicholas

Abstract excerpt

Most patients with cancer either do not respond to immune checkpoint blockade or develop resistance to it, often because of acquired mutations that impair antigen presentation. Here we show that loss of function of the RNA-editing enzyme ADAR1 in tumour cells profoundly sensitizes tumours to immunotherapy and overcomes resistance to checkpoint blockade. In the absence of ADAR1, A-to-I editing of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenosine Deaminase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Cycle Checkpoints

Share to Interferon-Induced Helicase, IFIH1

Share to Interferons

Share to Melanoma, Experimental

Share to Programmed Cell Death 1 Receptor

Share to RNA, Double-Stranded

Share to RNA Editing

Source

Open in PubMed Open full text

Identifiers

PMID: 30559380
DOI: 10.1038/s41586-018-0768-9
PMCID: PMC7241251

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Loss of ADAR1 in tumours overcomes resistance to immune checkpoint blockade.PMID 30559380Read ↗

Targeting MDA5 enhances tumor immunity through immunogenic cell death and augments the efficacy of immune checkpoint blockadeSemantic proximity Read ↗

The Crossroads of Cancer Epigenetics and Immune Checkpoint TherapySemantic proximity Read ↗

ADAR1 editing dependency in triple-negative breast cancerSemantic proximity Read ↗

ADAR1-mediated RNA editing promotes B cell lymphomagenesisSemantic proximity Read ↗

All-trans retinoic acid-mediated ADAR1 degradation synergizes with PD-1 blockade to suppress pancreatic cancerSemantic proximity Read ↗

<i>Setdb1</i> -loss induces type-I interferons and immune clearance of melanomaSemantic proximity Read ↗

Malignant A-to-I RNA editing by ADAR1 drives T cell acute lymphoblastic leukemia relapse via attenuating dsRNA sensingSemantic proximity Read ↗

ADAR1: “Editor-in-Chief” of Cytoplasmic Innate ImmunitySemantic proximity Read ↗

The role of RNA editing by ADAR1 in prevention of innate immune sensing of self-RNASemantic proximity Read ↗

Autocrine interferon poisoning mediates ADAR1-dependent synthetic lethality in BRCA1/2-mutant cancers.Semantic proximity Read ↗

MLLT6 maintains PD‐L1 expression and mediates tumor immune resistanceSemantic proximity Read ↗

Reprogramming the anti-tumor immune response via CRISPR genetic and epigenetic editingSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.